Form 4 for OTLK Outlook Therapeutics, Inc.
Accepted 2022-10-11 00:00:00 ET · period of report 2022-10-07 · accession 0001209191-22-053357 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-10-11 | 2022-10-07 | OTLK | Sukhtian Faisal Ghiath | Dir | P - Purchase | $1.29 | +30.0K | 68.0K | +79% | +$38.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-10-07 | P | A | 30,000 | $1.29 | 68,000 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.29 - $1.295, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. (F2) Reflects the amount of securities beneficially owned by the Reporting Person following the reported transaction herein and corrects the erroneous Form 4 filed with the Securities and Exchange Commission on April 22, 2022 (the "April 22, 2022 Filing"), pursuant to which a total of 55,816,786 shares were reported as indirectly beneficially owned (by GMS Ventures) on Table I. These shares are indirectly beneficially owned by Ghiath M. Sukhtian (CIK number 0001717441) and not by the Reporting Person. The April 22, 2022 Filing was erroneously made under the Reporting Person's CIK number. |